Cargando…

A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)

Patient: Female, 24-year-old Final Diagnosis: K2 induced posterior reversible encephalopathy syndrome Symptoms: Abnormal behavior • headache Medication: — Clinical Procedure: — Specialty: General and Internal Medicine • Toxicology OBJECTIVE: Unusual clinical course BACKGROUND: K2 is an artificially...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghazanfar, Haider, Muthumanickam, Aruna, Qureshi, Zaheer, Altaf, Faryal, Zeana, Cosmina, Chilimuri, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059105/
https://www.ncbi.nlm.nih.gov/pubmed/35470354
http://dx.doi.org/10.12659/AJCR.936209
_version_ 1784698242534998016
author Ghazanfar, Haider
Muthumanickam, Aruna
Qureshi, Zaheer
Altaf, Faryal
Zeana, Cosmina
Chilimuri, Sridhar
author_facet Ghazanfar, Haider
Muthumanickam, Aruna
Qureshi, Zaheer
Altaf, Faryal
Zeana, Cosmina
Chilimuri, Sridhar
author_sort Ghazanfar, Haider
collection PubMed
description Patient: Female, 24-year-old Final Diagnosis: K2 induced posterior reversible encephalopathy syndrome Symptoms: Abnormal behavior • headache Medication: — Clinical Procedure: — Specialty: General and Internal Medicine • Toxicology OBJECTIVE: Unusual clinical course BACKGROUND: K2 is an artificially synthesized cannabinoid (SCB), manufactured as a non-consumption herbal incense but increasingly misused as a recreational drug. Posterior reversible encephalopathy syndrome (PRES) is a rare clinical and radiological entity characterized by brain edema, often in the setting of acute hypertension. Cases of PRES caused by recreational drug use have been reported in the literature. CASE REPORT: We report an unusual case of PRES after consumption of K2 in a 24-year-old healthy woman who presented with episodic agitation and altered mental status. Magnetic resonance imaging showed nonspecific subtle high T2/FLAIR (fluid-attenuated inversion recovery) signal intensities in the region of the posterior parietal and occipital cortices. Her extensive drug screen report was positive for K2. Her mental status improved over the course of 3 weeks and she had returned to her baseline at 3-month follow-up. CONCLUSIONS: Our case highlights the importance of having a high clinical suspicion in patients presenting with altered mental status and a history of recreational drug use. K2 is not detected by routine urine drug testing, so a high level of clinical suspicion is required to request an extensive drug screen. It is important for the physician to counsel active synthetic cannabinoid users regarding these rare complications.
format Online
Article
Text
id pubmed-9059105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-90591052022-05-17 A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) Ghazanfar, Haider Muthumanickam, Aruna Qureshi, Zaheer Altaf, Faryal Zeana, Cosmina Chilimuri, Sridhar Am J Case Rep Articles Patient: Female, 24-year-old Final Diagnosis: K2 induced posterior reversible encephalopathy syndrome Symptoms: Abnormal behavior • headache Medication: — Clinical Procedure: — Specialty: General and Internal Medicine • Toxicology OBJECTIVE: Unusual clinical course BACKGROUND: K2 is an artificially synthesized cannabinoid (SCB), manufactured as a non-consumption herbal incense but increasingly misused as a recreational drug. Posterior reversible encephalopathy syndrome (PRES) is a rare clinical and radiological entity characterized by brain edema, often in the setting of acute hypertension. Cases of PRES caused by recreational drug use have been reported in the literature. CASE REPORT: We report an unusual case of PRES after consumption of K2 in a 24-year-old healthy woman who presented with episodic agitation and altered mental status. Magnetic resonance imaging showed nonspecific subtle high T2/FLAIR (fluid-attenuated inversion recovery) signal intensities in the region of the posterior parietal and occipital cortices. Her extensive drug screen report was positive for K2. Her mental status improved over the course of 3 weeks and she had returned to her baseline at 3-month follow-up. CONCLUSIONS: Our case highlights the importance of having a high clinical suspicion in patients presenting with altered mental status and a history of recreational drug use. K2 is not detected by routine urine drug testing, so a high level of clinical suspicion is required to request an extensive drug screen. It is important for the physician to counsel active synthetic cannabinoid users regarding these rare complications. International Scientific Literature, Inc. 2022-04-26 /pmc/articles/PMC9059105/ /pubmed/35470354 http://dx.doi.org/10.12659/AJCR.936209 Text en © Am J Case Rep, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Ghazanfar, Haider
Muthumanickam, Aruna
Qureshi, Zaheer
Altaf, Faryal
Zeana, Cosmina
Chilimuri, Sridhar
A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
title A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
title_full A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
title_fullStr A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
title_full_unstemmed A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
title_short A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
title_sort case of synthetic cannabinoid (k2)-induced posterior reversible encephalopathy syndrome (pres)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059105/
https://www.ncbi.nlm.nih.gov/pubmed/35470354
http://dx.doi.org/10.12659/AJCR.936209
work_keys_str_mv AT ghazanfarhaider acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT muthumanickamaruna acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT qureshizaheer acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT altaffaryal acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT zeanacosmina acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT chilimurisridhar acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT ghazanfarhaider caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT muthumanickamaruna caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT qureshizaheer caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT altaffaryal caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT zeanacosmina caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres
AT chilimurisridhar caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres